Literature DB >> 15238090

CD28nullCD4+ T cells--characterization of an effector memory T-cell population in patients with rheumatoid arthritis.

A E R Fasth1, D Cao, R van Vollenhoven, C Trollmo, V Malmström.   

Abstract

CD4+ T cells lacking the costimulatory molecule CD28 have been described both in elderly individuals and in chronic inflammatory disorders, one being rheumatoid arthritis (RA). We, in this study, provide a comprehensive characterization of cell surface markers on and function of such CD28nullCD4+ T cells, as well as correlations with clinical parameters. We conclude that of all surface markers associated with these cells, only CD57 and CD11b are expressed on the majority of them. This CD28null population occurred in one-third of patients with RA and was independent of clinical characteristics. The population was persistent and expanded in peripheral blood, but was excluded from the joint in most patients. Functionally, CD28nullCD4+ T cells were potent effector memory cells with regard to their proliferation and cytokine-secretion profiles. This capacity correlated with a hitherto unpublished surface phenotype, the cells being uniformly CCR7- and CD43high. Moreover, a new terminally differentiated CD45RA+CCR7- population of CD4+ T cells was identified. We would like to suggest that in the unbalanced immune system of patients with autoimmune disease and chronic infection an expanded CD28nullCD4+ T-cell population able to secrete high levels of cytokines is likely to contribute to disease manifestations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238090     DOI: 10.1111/j.0300-9475.2004.01464.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  32 in total

1.  Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.

Authors:  D Eastwood; L Findlay; S Poole; C Bird; M Wadhwa; M Moore; C Burns; R Thorpe; R Stebbings
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.

Authors:  Philippe Azam; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Stephen Griffey; Heike Wulff
Journal:  J Invest Dermatol       Date:  2007-02-01       Impact factor: 8.551

3.  Memory T cells specific to citrullinated α-enolase are enriched in the rheumatic joint.

Authors:  Jennifer Pieper; Anatoly Dubnovitsky; Christina Gerstner; Eddie A James; Mary Rieck; Genadiy Kozhukh; Karolina Tandre; Sara Pellegrino; John A Gebe; Lars Rönnblom; Tatyana Sandalova; William W Kwok; Lars Klareskog; Jane H Buckner; Adnane Achour; Vivianne Malmström
Journal:  J Autoimmun       Date:  2018-05-28       Impact factor: 7.094

4.  CD28neg. T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs.

Authors:  Hisayoshi Hashimoto; Marco Sterk; Karin Schilbach
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 5.  Genetics in PSC: what do the "risk genes" teach us?

Authors:  Trine Folseraas; Evaggelia Liaskou; Carl A Anderson; Tom H Karlsen
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

6.  Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.

Authors:  Rongsheng E Wang; Ying Wang; Yuhan Zhang; Chase Gabrelow; Yong Zhang; Victor Chi; Qiangwei Fu; Xiaozhou Luo; Danling Wang; Sean Joseph; Kristen Johnson; Arnab K Chatterjee; Timothy M Wright; Vân T B Nguyen-Tran; John Teijaro; Argyrios N Theofilopoulos; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

Review 7.  Synthetic DNA approach to cytomegalovirus vaccine/immune therapy.

Authors:  Stephan J Wu; Daniel O Villarreal; Devon J Shedlock; David B Weiner
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 8.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

Review 9.  Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?

Authors:  Vivianne Malmström; Christina Trollmo; Lars Klareskog
Journal:  Arthritis Res Ther       Date:  2005-03-16       Impact factor: 5.156

10.  Association of Elevations of Specific T Cell and Monocyte Subpopulations in Rheumatoid Arthritis With Subclinical Coronary Artery Atherosclerosis.

Authors:  Robert Winchester; Jon T Giles; Simona Nativ; Kendall Downer; Hui-Zhu Zhang; Ayse Bag-Ozbek; Afshin Zartoshti; Sabahat Bokhari; Joan M Bathon
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.